{"database": "lobbying", "table": "lobbying_activities", "rows": [[1341558, "82824ec3-a6d4-4527-8909-fca9cdd9522d", "Q4", "APOTEX CORP.", 310973, "APOTEX CORP.", 2012, "fourth_quarter", "PHA", "S. 1882, The Fair and Immediate Release of Generics Act\nS. 27, The Preserve Access to Affordable Pharmaceuticals Act\nActelion Pharmaceutical LTD and Actelion Clinical Research Inc. V. Apotex Inc., Apotex Corp., and Roxane Laboratories Inc. The use of Risk Evaluation and Mitigation Strategies (REMS) by brand drug companies to delay generic competition\nEstablishment of a federal track and trace system for pharmaceuticals\nAdoption of an electronic labeling system for pharmaceuticals", "HOUSE OF REPRESENTATIVES,SENATE", null, 90000, 0, 0, "2013-01-18T09:33:42.217000-05:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["1341558"], "units": {}, "query_ms": 58.99219703860581, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}